Paul E. Jahn is a partner in and until recently served as co-chair of the firm’s Technology Transactions Group. His practice is focused on counseling companies with respect to intellectual property matters, particularly with respect to the development, licensing, acquisition, and sale of intellectual property and technology; strategic alliances and joint ventures; distribution and commercialization arrangements; outsourcing; branding agreements; and the settlement of related disputes. These transactions generally involve hardware, software, electronic commerce, the Internet, the life sciences, telecommunications, or other advanced technology. Mr. Jahn has extensive international experience, having been resident in offices of the firm and involved in major transactions in the United States, Asia, and Europe. He has been listed as a Leading IT Outsourcing Lawyer in California by Chambers USA (2005 and 2006) and a Northern California Super Lawyer by San Francisco Magazine (2005 and 2006). Representative clients include Ask Jeeves, Charles Schwab, Chiron, Dreamworks, EchoStar, Fujitsu, Hitachi, Lucasfilm, Thomson, and the University of California.

Before obtaining his law degree, Mr. Jahn practiced as a legislative advocate in Brussels, Belgium, representing a coalition of major computer product manufacturers in a campaign to influence the content of a European Community directive concerning the scope of copyright protection for software. Prior to that time, he worked in Tokyo as part of a technical team representing Fujitsu in its arbitration with IBM involving copyrights for operating system software.

Mr. Jahn has served as intellectual property and licensing counsel for:

• Hitachi in its $2.05 billion deal to combine its hard disk drive operations with those of IBM, including the negotiation of all technology transfer aspects of the transaction and advising Hitachi with respect to strategic licensing issues.
  
  
• Fujitsu in the restructuring of its flash memory joint venture with AMD.
  
  
• EchoStar in settlement and patent licensing negotiations with Gemstar.
  
  
• Chiron in its negotiations with Roche relating to royalties due for use of Chiron’s blood screening patents.